Scancell shares healthy following patent approval award in Japan

Shares in cancer vaccine developer Scancell rose on Wednesday after the company announced its ImmunoBody Patent had been approved in Japan.

The same patent has already been approved in the US, Europe and Australia.

Dr Richard Goodfellow, Joint Chief Executive Officer of Scancell, commented: "This is a further important step in the development and commercialisation of the ImmunoBody platform and provides further evidence to support the novelty of Scancell's ImmunoBody technology in another key pharmaceutical market.

MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free

https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

"Scancell will continue building its growing portfolio of intellectual property in parralel with driving the clinical trial programme on SCIBI forward during 2013."

SCIBI is Scancell's first cancer vaccine which is currently being developed for the treatment of melanoma.

Scancell's share price was up 6.37% to 41.75p at 11:01 on Wednesday.

MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.